Dr. Michael S. Perry, MD
Child Neurology (Neurology with Special Qualifications in Child Neurology Physician)
At a glance
- In the NPI registry since
- 2007
Licensed in Texas since 2008, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology with Special Qualifications in Child Neurology Physician primary
TX license N1416 (first issued 2008; active) -
Pediatric Neurodevelopmental Disabilities Physician
GA license 054308
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 5 companies reported 34 payments worth $19,394 in total to this clinician.
| UCB SA | $6,870 |
|---|---|
| Neurelis, Inc. | $5,927 |
| UCB, Inc. | $4,850 |
| Biocodex, Inc. | $1,209 |
| Jazz Pharmaceuticals Inc. | $538 |
| Consulting Fee | $17,191 |
|---|---|
| Food and Beverage | $1,302 |
| Travel and Lodging | $902 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Neurelis, Inc. Dec 23, 2025 | Consulting Fee VALTOCO · EPILEPSY | $5,346 |
| UCB, Inc. Dec 4, 2025 | Consulting Fee Fintepla · Neurology | $4,400 |
| UCB SA Dec 5, 2025 | Consulting Fee Fintepla · Neurology | $2,200 |
| UCB SA Jul 16, 2025 | Consulting Fee | $1,920 |
| UCB SA Mar 7, 2025 | Consulting Fee | $1,650 |
| UCB SA Jul 16, 2025 | Consulting Fee Fintepla · Neurology | $1,100 |
| Biocodex, Inc. May 6, 2025 | Consulting Fee DIACOMIT · Antiepileptic | $575 |
| Neurelis, Inc. Dec 23, 2025 | Travel and Lodging VALTOCO · EPILEPSY · travel to ATLANTA, GA | $381 |
| Biocodex, Inc. Dec 11, 2025 | Travel and Lodging DIACOMIT · Antiepileptic · travel to CHANDLER, AZ | $269 |
| Neurelis, Inc. Dec 5, 2025 | Travel and Lodging VALTOCO · EPILEPSY · travel to ATLANTA, GA · in-kind | $122 |
All 14 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Neurelis, Inc. Dec 23, 2025 | Consulting Fee VALTOCO · EPILEPSY | $5,346 |
| Neurelis, Inc. Dec 23, 2025 | Travel and Lodging VALTOCO · EPILEPSY · travel to ATLANTA, GA | $381 |
| Neurelis, Inc. Dec 23, 2025 | Travel and Lodging VALTOCO · EPILEPSY · travel to FORT WORTH, TX | $57.72 |
| Neurelis, Inc. Dec 23, 2025 | Travel and Lodging VALTOCO · EPILEPSY · travel to FORT WORTH, TX | $21.00 |
| UCB, Inc. Dec 12, 2025 | Travel and Lodging Fintepla · Neurology · travel to Dallas, TX | $47.60 |
| UCB, Inc. Dec 12, 2025 | Travel and Lodging Fintepla · Neurology · travel to Dallas, TX | $4.00 |
| Biocodex, Inc. Dec 11, 2025 | Travel and Lodging DIACOMIT · Antiepileptic · travel to CHANDLER, AZ | $269 |
| UCB SA Dec 5, 2025 | Consulting Fee Fintepla · Neurology | $2,200 |
| Neurelis, Inc. Dec 5, 2025 | Travel and Lodging VALTOCO · EPILEPSY · travel to ATLANTA, GA · in-kind | $122 |
| UCB, Inc. Dec 4, 2025 | Consulting Fee Fintepla · Neurology | $4,400 |
| UCB SA Jul 16, 2025 | Consulting Fee | $1,920 |
| UCB SA Jul 16, 2025 | Consulting Fee Fintepla · Neurology | $1,100 |
| Biocodex, Inc. May 6, 2025 | Consulting Fee DIACOMIT · Antiepileptic | $575 |
| UCB SA Mar 7, 2025 | Consulting Fee | $1,650 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $46,872 in research payments for these studies, mostly to the institutions running them.
- A phase 2, prospective, interventional, open-label, multi-site, extension study to assess the long-term safety and tolerability of TAK-935 (OV935) as adjunctive therapy in patients with rare epilepsy
Takeda Pharmaceuticals U.S.A., Inc. - A study of soticlestat as an add-on therapy in children and adults with dravet syndrome or lennox-gastaut syndrome
Takeda Pharmaceuticals U.S.A., Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.